Therapeutic Asset Ratings
622 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Oki-219
Breast Cancer
OnKure, Inc.
P1
C
(36)
pf-07224826
Breast Cancer
Pfizer
P1
C
(36)
P-Muc1C-Allo1 Car-T Cells
Breast Cancer
Poseida Therapeutics, Inc.
P1
C
(36)
Pvx-410
Breast Cancer
Massachusetts General Hospital
P1
C
(36)
QXL138AM
Breast Cancer
Nammi Therapeutics Inc
P1
C
(36)
Recombinant Humanized Type Iii Collagen
Breast Cancer
Peking University People's Hospital
P1
C
(36)
Rgt-419B
Breast Cancer
Regor Pharmaceuticals Inc.
P1
C
(36)
Rgt-490
Breast Cancer
Regor Pharmaceuticals Inc.
P1
C
(36)
Rimiducid
Breast Cancer
M.D. Anderson Cancer Center
P1
C
(36)
SAR443216
Breast Cancer
Sanofi
P1
C
(36)
Son-Dp
Breast Cancer
Qurgen Inc.
P1
C
(36)
syn608
Breast Cancer
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
P1
C
(36)
syn818
Breast Cancer
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
P1
C
(36)
sys6043
Breast Cancer
Conjupro Biotherapeutics, Inc.
P1
C
(36)
tas2940
Breast Cancer
Taiho Oncology, Inc.
P1
C
(36)
Tazemetostat
Breast Cancer
Dana-Farber Cancer Institute
P1
C
(36)
Tbio-4101
Breast Cancer
Turnstone Biologics, Corp.
P1
C
(36)
Valemetostat
Breast Cancer
M.D. Anderson Cancer Center
P1
C
(36)
Vsv-02
Breast Cancer
The First Affiliated Hospital of Xinxiang Medical College
P1
C
(36)
99mTc-ABH2
Breast Cancer
Peking Union Medical College Hospital
Early P1
C
(36)
Pacritinib
Breast Cancer
National University Hospital, Singapore
P1/2
C
(36)
egf816
Breast Cancer
M.D. Anderson Cancer Center
P1/2
C
(35)
Benralizumab
Breast Cancer
Memorial Sloan Kettering Cancer Center
P2
C
(33)
Tas-109
Breast Cancer
Dana-Farber Cancer Institute
P1
C
(33)
[177Lu]Lu-HT547
Breast Cancer
Hua Pang
Early P1
C
(33)
Showing 526 to 550 of 622 assets
Previous
Page 22 of 25
Next